Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: a single center experience

Clicks: 253
ID: 117312
1970
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #23 of 85 articles by views in Annals of hematology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Several trials have suggested that intensive post-remission therapy may prolong the duration of complete remission (CR) in acute myeloid leukemia (AML). The purpose of this study was to evaluate the feasibility and the efficacy of high-dose cytarabine (HiDAC) consolidation chemotherapy followed by high-dose therapy and autologous infusion of peripheral blood progenitor cells (PBPC) mobilized by G-CSF in adult patients with AML in first CR. Fifteen consecutive AML patients underwent HiDAC consolidation chemotherapy, used as a method of in vivo purging, followed by G-CSF for the purpose of autologous PBPC collection. Eleven patients collected a median of 6.9×108/kg peripheral blood mononuclear cells (MNC) (range 2.9–23) and a median of 6.67×106/kg CD34+ cells (range 1.8–33.5) with a median of two aphereses (range 1–3). Two patients did not mobilize and two obtained an inadequate number of progenitor cells. The 11 patients with adequate collections received myeloablative chemotherapy followed by the infusion of PBPC. The median number of days to recover neutrophils and platelets was 12 and 13, respectively. After a median follow-up of 28.7 months (range 17.2–43.4), five out of 11 patients who underwent PBPC transplantation are still in CR, five have died in first relapse and one is alive in CR after relapse treated with salvage therapy and second PBPC infusion. These results demonstrate that HiDAC consolidation chemotherapy followed by autologous PBPC transplantation is a feasible procedure with minimal toxicity. Randomized studies should be performed to evaluate whether this form of consolidation may produce a significant improvement in leukemia-free survival.
Reference Key
castagnola1970annalsconsolidation Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Carlo Castagnola;Emilio Alessandrino;Monia Lunghi;Paolo Bernasconi;Matteo Della Porta;Silvia Mangiacavalli;Anna Colombo;Alessandro Corso;Guido Pagnucco;Mario Lazzarino;Carlo Bernasconi;Carlo Castagnola;Emilio Alessandrino;Monia Lunghi;Paolo Bernasconi;Matteo Della Porta;Silvia Mangiacavalli;Anna Colombo;Alessandro Corso;Guido Pagnucco;Mario Lazzarino;Carlo Bernasconi;
Journal Annals of hematology
Year 1970
DOI
doi:10.1007/s002770000277
URL
https://link.springer.com/article/10.1007/s002770000277
Keywords
oncology hematology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.